Advanced search
Start date
Betweenand
(Reference retrieved automatically from Web of Science through information on FAPESP grant and its corresponding number as mentioned in the publication by the authors.)

Control of experimental pulmonary tuberculosis depends more on immunostimulatory leukotrienes than on the absence of immunosuppressive prostaglandins

Full text
Author(s):
Peres-Buzalaf, C. [1] ; de Paula, L. [1] ; Frantz, F. G. [1] ; Soares, E. M. [1] ; Medeiros, A. I. [1] ; Peters-Golden, M. [2] ; Silva, C. L. [3] ; Faccioli, L. H. [1]
Total Authors: 8
Affiliation:
[1] Univ Sao Paulo, Dept Anal Clin Toxicol & Bromatol, Fac Ciencias Farmaceut Ribeirao Preto, BR-14040903 Sao Paulo - Brazil
[2] Univ Michigan Hlth Syst, Div Pulm & Crit Care Med, Dept Internal Med, Ann Arbor, MI - USA
[3] Univ Sao Paulo, Dept Bioquim & Imunol, Fac Med Ribeirao Preto, BR-14049900 Sao Paulo - Brazil
Total Affiliations: 3
Document type: Journal article
Source: PROSTAGLANDINS LEUKOTRIENES AND ESSENTIAL FATTY ACIDS; v. 85, n. 2, p. 75-81, AUG 2011.
Web of Science Citations: 18
Abstract

Prostaglandins (PGs) and leukotrienes (LTs) are produced in Mycobacterium tuberculosis (Mtb)-infected lungs and have immune suppressive and protective effects, respectively. Considering that both of these mediators are produced during mycobacterial infection, we investigated the specific and relative biological importance of each in regulating host response in experimental tuberculosis. Administration of celecoxib, which was found to reduce lung levels of PGE(2) and increase LTB(4), enhanced the 60-day survival of Mtb-infected mice in 14%. However administration of MK-886, which reduced levels of LTB(4) but did not enhance PGE(2), reduced 60-day survival from 86% to 43% in Mtb-infected mice, and increased lung bacterial burden. MK-886 plus celecoxib reduced survival to a lesser extent than MK-886 alone. MK-886- and MK-886 plus celecoxib-treated animals exhibited reduced levels of the protective interleukin-12 and gamma-interferon. Our findings indicate that in this model, the protective effect of LTs dominates over the suppressive effect of PGs. (C) 2011 Elsevier Ltd. All rights reserved. (AU)

FAPESP's process: 02/12856-2 - Modulation of innate and acquired immune responses by leukotrienes and prostaglandins
Grantee:Lúcia Helena Faccioli
Support Opportunities: Research Projects - Thematic Grants
FAPESP's process: 00/09663-2 - Preclinical gene therapy tests against Tuberculosis which could shorten the duration of treatment, improve the treatment of latent infection and could be effective against MDR-TB
Grantee:Celio Lopes Silva
Support Opportunities: Research Projects - Thematic Grants